CPHRF (Cipher Pharmaceuticals) Moat Score: 3/10 (As of Jul. 01, 2026)


CPHRF Cipher Pharmaceuticals Inc CPHRF
96 GF Score
Price $11.77
GF Value $12.21
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Cipher Pharmaceuticals Moat Score?

Cipher Pharmaceuticals CPHRF +1.60% 96 Moat Score is 3 as of Jul. 01, 2026. GuruFocus rates CPHRF with a GF Score™ of 96/100 and a GF Value™ of $12.21 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Cipher Pharmaceuticals ranks better than 86.13% on this metric.

Cipher Pharmaceuticals has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Cipher Pharmaceuticals has No Moat: Cipher Pharmaceuticals lacks significant market leadership and customer loyalty. It does not possess strong intellectual property or regulatory barriers, and its pricing power is limited. The company operates in a competitive pharmaceutical market with minimal switching costs and no significant cost advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Cipher Pharmaceuticals might have No Moat - Very weak/transient advantages.

Cipher Pharmaceuticals  (OTCPK:CPHRF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Cipher Pharmaceuticals Moat Score Related Terms

CPHRF vs ZTS, UTHR: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cipher Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cipher Pharmaceuticals Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cipher Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Cipher Pharmaceuticals's Moat Score falls into.


CPHRF
96GF Score
Cipher Pharmaceuticals Inc CPHRF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Cipher Pharmaceuticals (CPHRF) has a Moat Score of 3 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Cipher Pharmaceuticals ranks #143 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 13.9%.
Is Cipher Pharmaceuticals' Moat Score too high?
Cipher Pharmaceuticals' current Moat Score is 3. Based on the distribution chart, Cipher Pharmaceuticals ranks #143 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cipher Pharmaceuticals has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cipher Pharmaceuticals' Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cipher Pharmaceuticals ranks #143 out of 1031 companies for Moat Score. This places Cipher Pharmaceuticals in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Cipher Pharmaceuticals's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipher Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cipher Pharmaceuticals (CPHRF) is currently considered Fairly Valued. The stock's GF Value™ is $12.21, compared to a current price of $11.77 — trading 3.6% below its estimated fair value. The current Moat Score is 3. Cipher Pharmaceuticals' overall GF Score™ is 96/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Cipher Pharmaceuticals (CPHRF), the current Moat Score is 3 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cipher Pharmaceuticals (CPHRF) Overvalued in 2026?

Based on GuruFocus' analysis, Cipher Pharmaceuticals stock appears to be undervalued. The current stock price of $11.77 is trading 3.6% below its estimated GF Value™ of $12.21. GuruFocus considers Cipher Pharmaceuticals to be Fairly Valued.

Key valuation signals for CPHRF:

  • Moat Score: 3
  • GF Value™: $12.21 vs. price of $11.77 (3.6% below fair value)
  • GF Score™: 96/100 with 5 warning signs

No single metric tells the full story. See the CPHRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cipher Pharmaceuticals Business Description

Other Exchanges PHE:GermanyCPH:Canada
Address 5750 Explorer Drive, Suite 404, Mississauga, ON, CAN, L4W 0A9
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing, and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products, among others. The company's geographical operational areas include Canada and the United States.
96GF Score

Get the complete analysis for CPHRF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.77
Price
$12.21
GF Value